Increased resistance to current anti-HER2 therapies has led to the development of novel therapies to treat HER2-positive breast cancer, including antibody-drug conjugate (ADCs), bispecific antibodies, chimeric antigen receptor T-cell therapy (CAR-T), immunotherapy, and nanotherapy [71]. This evidence concerns the gene ERBB2 and breast carcinoma.